SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders
SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors. In addition to her role as a non-executive Director, Ms. Allen will serve as the Chair of SwanBio’s Audit Committee.